Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory Study

NCT06238752 is registered in ClinicalTrials.gov with Renmin Hospital of Wuhan University as lead sponsor.

NCT NCT06238752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory Study
Lead sponsor
Renmin Hospital of Wuhan University
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
January 1, 2024
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma